Recent clinical and research development supports the use of 5-fluorouracil in combination with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5-Fluorouracil (5-FU), which is as an anti-metabolite, is a widely used cytostatic drug. Although the rate of response, quality of life and overall survival differs between CRC patients, the above combination remains a widely used chemotherapeutic regimen. In some cases, a cancer stem cell (CSC) population may resist the majority of chemotherapeutic models. This study investigated if monotherapy is more efficacious than 5-fluorouracil and oxaliplatin combined for the treatment of CRC, using a CRC cell line and a CSC-like line. Cell viability was evaluated by cellular-based assays, and quantitative polymerase chain reaction (q-PCR) assays were performed to assess the expression of specific genes ( TYMS , DNMT 1, NANOG , DHFR, SHMT1, ERCC1, DPYD) correlated with 5-FU and oxaliplatin resistance. We observed that 5-fluorouracil was more effective in both CRC and CSCs. This finding proved the hypothesis that, in some cases, monotherapy may be more successful in CRC treatment than a drug combination that may be cytotoxic and inflict adverse side effects.
Keywords5-FluorouracilOxaliplatinFOLFOXColon Cancer Stem Cells
Haggar, F.A. and Boushey, R.P. (2009) Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clinics in Colon and Rectal Surgery, 22, 191-197. http://dx.doi.org/10.1055/s-0029-1242458
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H.T., Minsky, B., Nordlinger, B. and Starling, N. (2010) Colorectal Cancer. The Lancet, 375, 1030-1047. http://dx.doi.org/10.1016/S0140-6736(10)60353-4
Wasserberg, N. and Kaufman, H.S. (2007) Palliation of Colorectal Cancer. Surgical Oncology, 16, 299-310. http://dx.doi.org/10.1016/j.suronc.2007.08.008
Chau, I. and Cunningham, D. (2002) Adjuvant Therapy in Colon Cancer: Current Status and Future Directions. Cancer Treatment Reviews, 28, 223-236. http://dx.doi.org/10.1016/S0305-7372(02)00047-6
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 18, 2938-2947.
Shim, B.Y., Lee, K.M., Cho, H.-M., Kim, H.J., Cho, H.J., Yang, J., Kim, J.-G. and Kim, H.-K. (2005) Oxaliplatin/ 5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer. Cancer Research and Treatment, 37, 212-215. http://dx.doi.org/10.4143/crt.2005.37.4.212
Dean, M., Fojo, T. and Bates, S. (2005) Tumour Stem Cells and Drug Resistance. Nature Reviews Cancer, 5, 275-284. http://dx.doi.org/10.1038/nrc1590
Woodward, W.A., Chen, M.S., Behbod, F., Alfaro, M.P., Buchholz, T.A. and Rosen, J.M. (2007) WNT/Beta-Catenin Mediates Radiation Resistance of Mouse Mammary Progenitor Cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 618-623. http://dx.doi.org/10.1073/pnas.0606599104
Liu, G.T., Yuan, X.P., Zeng, Z.H., Tunici, P., Ng, H., Abdulkadir, I.R., Lu, L.Z., Irvin, D., Black, K.L. and Yu, J.S. (2006) Analysis of Gene Expression and Chemoresistance of CD133+ Cancer Stem Cells in Glioblastoma. Molecular Cancer, 5, 67. http://dx.doi.org/10.1186/1476-4598-5-67
Dean, M. (2009) ABC Transporters, Drug Resistance, and Cancer Stem Cells. Journal of Mammary Gland Biology and Neoplasia, 14, 3-9. http://dx.doi.org/10.1007/s10911-009-9109-9
Liu, Y.B., Peterson, D.A., Kimura, H. and Schubert, D. (1997) Mechanism of Cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Reduction. Journal of Neurochemistry, 69, 581-593. http://dx.doi.org/10.1046/j.1471-4159.1997.69020581.x
Stockert, J.C., Blazquez-Castro, A., Canete, M., Horobin, R.W. and Villanueva, A. (2012) MTT Assay for Cell Viability: Intracellular Localization of the Formazan Product Is in Lipid Droplets. Acta Histochemica, 114, 785-796. http://dx.doi.org/10.1016/j.acthis.2012.01.006
van Meerloo, J., Kaspers, G.J. and Cloos, J. (2011) Cell Sensitivity Assays: The MTT Assay. Cancer Cell Culture Methods in Molecular Biology, 731, 237-245. http://dx.doi.org/10.1007/978-1-61779-080-5_20
Sylvester, P.W. (2011) Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular Growth and Viability. Drug Design and Discovery Methods in Molecular Biology, 716, 157-168. http://dx.doi.org/10.1007/978-1-61779-012-6_9
Liu, Y.B. and Nair, M.G. (2010) An Efficient and Economical MTT Assay for Determining the Antioxidant Activity of Plant Natural Product Extracts and Pure Compounds. Journal of Natural Products, 73, 1193-1195. http://dx.doi.org/10.1021/np1000945
Ashraf, H., Taherian, A. and Kerdar, A.N. (2010) Evaluation of Cytotoxicity of Two Root Canal Filling Materials by MTT Assay. Australian Endodontic Journal, 36, 24-28. http://dx.doi.org/10.1111/j.1747-4477.2009.00173.x
Han, F.X., Lin, H. and Ru, L. (2009) MTT Assay for Detecting 5-Fluorouracil Chemosensitivity of Human Breast Carcinoma Cell Line. Journal of Southern Medical University, 29, 97-99.
Vichai, V. and Kirtikara, K. (2006) Sulforhodamine B Colorimetric Assay for Cytotoxicity Screening. Nature Protocols, 1, 1112-1116. http://dx.doi.org/10.1038/nprot.2006.179
Voigt, W. (2005) Sulforhodamine B Assay and Chemosensitivity. Chemosensitivity Methods in Molecular Medicine, 110, 39-48. http://dx.doi.org/10.1385/1-59259-869-2:039
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S. and Boyd, M.R. (1990) New Colorimetric Cytotoxicity Assay for anticancer-Drug Screening. Journal of the National Cancer Institute, 82, 1107-1112. http://dx.doi.org/10.1093/jnci/82.13.1107
Houghton, P., Fang, R., Techatanawat, I., Steventon, G., Hylands, P.J. and Lee, C.C. (2007) The Sulphorhodamine (SRB) Assay and Other Approaches to Testing Plant Extracts and Derived Compounds for Activities Related to Reputed Anticancer Activity. Methods, 42, 377-387. http://dx.doi.org/10.1016/j.ymeth.2007.01.003
Bonnekoh, B., Wevers, A., Jugert, F., Merk, H. and Mahrle, G. (1989) Colorimetric Growth Assay for Epidermal Cell Cultures by Their Crystal Violet Binding Capacity. Archives of Dermatological Research, 281, 487-490. http://dx.doi.org/10.1007/BF00510085
Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y. and Ueno, K. (1996) A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet. Biological and Pharmaceutical Bulletin, 19, 1518-1520. http://dx.doi.org/10.1248/bpb.19.1518
Grady, J.E., Lummis, W.L. and Smith, C.G. (1960) An Improved Tissue Culture Assay. III. Alternate Methods for Measuring Cell Growth. Cancer Research, 20, 1114-1117.
Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408. http://dx.doi.org/10.1006/meth.2001.1262
Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J.-I., Yamamura, T. and Hashimoto-Tamaoki, T. (2001) Dual Antitumor Effects of 5-Fluorouracil on the Cell Cycle in Colorectal Carcinoma Cells: A Novel Target Mechanism Concept for Pharmacokinetic Modulating Chemotherapy. Cancer Research, 61, 1029-1037.
Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nature Reviews Cancer, 3, 330-338. http://dx.doi.org/10.1038/nrc1074
Jensen, S.A., Vainer, B., Witton, C.J., Jorgensen, J.T. and Sorensen, J.B. (2008) Prognostic Significance of Numeric Aberrations of Genes for Thymidylate Synthase, Thymidine Phosphorylase and Dihydrofolate Reductase in Colorectal Cancer. Acta Oncologica, 47, 1054-1061. http://dx.doi.org/10.1080/02841860801942158
Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K. and Hirayama, R. (2003) Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal Cancer. Clinical Cancer Research, 9, 786-791.
Steck, S.E., Keku, T., Butler, L.M., Galanko, J., Massa, B., Millikan, R.C. and Sandler, R.S. (2008) Polymorphisms in Methionine Synthase, Methionine Synthase Reductase and Serine Hydroxymethyltransferase, Folate and Alcohol Intake, and Colon Cancer Risk. Journal of Nutrigenetics and Nutrigenomics, 1, 196-204. http://dx.doi.org/10.1159/000136651
DiPaolo, A. and Chu, E. (2004) The Role of Thymidylate Synthase as a Molecular Biomarker. Clinical Cancer Research, 10, 411-412. http://dx.doi.org/10.1158/1078-0432.CCR-1198-03
Apostolou, P., Toloudi, M., Chatziioannou, M., and Papasotiriou, I. (2011) Predictive Value of Molecular-Cellular Methodologies for Response to Chemotherapy with CisPlatin/5Fu in Colon Tumours. Journal for Clinical Studies, 3, 28-32.
Salonga, D., Danenberg, K.D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D.D., Lenz, H.J., Leichman, C.G., Leichman, L., Diasio, R.B., et al. (2000) Colorectal Tumors Responding to 5-Fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, and Thymidine Phosphorylase. Clinical Cancer Research, 6, 1322-1327.
Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F.L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J.J., et al. (2007) Gene Expression of ERCC1 As a novel prognostic marker in Advanced Bladder Cancer Patients Receiving Cisplatin-Based Chemotherapy. Annals of Oncology, 18, 522-528. http://dx.doi.org/10.1093/annonc/mdl435
Yu, Y.J., Kanwar, S.S., Patel, B.B., Nautiyal, J., Sarkar, F.H. and Majumdar, A.P. (2009) Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Translational Oncology, 2, 321-328. http://dx.doi.org/10.1593/tlo.09193
Patel, B.B., Sengupta, R., Qazi, S., Vachhani, H., Yu, Y., Rishi, A.K. and Majumdar, A.P. (2008) Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Mediating Growth Inhibition of Colon Cancer Cells by Modulating EGFR and IGF-1R. International Journal of Cancer, 122, 267-273. http://dx.doi.org/10.1002/ijc.23097